Mario Gabelli Bristol Myers Squibb CO Transaction History

Gamco Investors, Inc. Et Al

$8.56 Billion
Q2 2024

A detailed history of Mario Gabelli (Gamco Investors, Inc. Et Al) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gamco Investors, Inc. Et Al holds 111,439 shares of BMY stock, worth $6.24 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

111,439

Previous 116,565 4.4%

Holding current value

$6.24 Million

Previous $6.32 Million 26.78%

% of portfolio

0.05%

Previous 0.07%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $206,321 - $271,626	-5,126 Reduced 4.4%	111,439 $4.63 Million
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $305,824 - $346,745	-6,374 Reduced 5.18%	116,565 $6.32 Million
Q3 2023 Nov 08, 2023	SELL	$57.89 - $64.73 $103,102 - $115,284	-1,781 Reduced 1.43%	122,939 $7.14 Million
Q2 2023 Aug 10, 2023	SELL	$63.71 - $70.74 $531,150 - $589,759	-8,337 Reduced 6.27%	124,720 $7.98 Million
Q1 2023 May 12, 2023	SELL	$65.71 - $74.53 $150,278 - $170,450	-2,287 Reduced 1.69%	133,057 $9.22 Million
Q4 2022 Feb 13, 2023	SELL	$68.48 - $81.09 $371,230 - $439,588	-5,421 Reduced 3.85%	135,344 $9.74 Million
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $91 - $54,249	-706 Reduced 0.5%	140,765 $10 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $1.15 Million - $1.26 Million	-15,783 Reduced 10.04%	141,471 $10.9 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $620,394 - $743,908	-10,091 Reduced 6.03%	157,254 $11.5 Million
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $783,534 - $913,417	-14,610 Reduced 8.03%	167,345 $10.4 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $372,771 - $436,653	6,300 Added 3.59%	181,955 $10.8 Million
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $419,068 - $456,365	-6,769 Reduced 3.71%	175,655 $11.7 Million
Q1 2021 May 14, 2021	SELL	$59.34 - $66.74 $415,854 - $467,713	-7,008 Reduced 3.7%	182,424 $11.5 Million
Q4 2020 Feb 05, 2021	SELL	$57.74 - $65.43 $1.05 Million - $1.19 Million	-18,230 Reduced 8.78%	189,432 $11.8 Million
Q3 2020 Nov 06, 2020	SELL	$57.43 - $63.64 $971,428 - $1.08 Million	-16,915 Reduced 7.53%	207,662 $12.5 Million
Q2 2020 Aug 13, 2020	SELL	$54.82 - $64.09 $16 Million - $18.7 Million	-292,473 Reduced 56.57%	224,577 $13.2 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $2.23 Million - $3.25 Million	48,138 Added 10.27%	517,050 $28.8 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $6.87 Million - $8.97 Million	139,692 Added 42.43%	468,912 $30.1 Million
Q3 2019 Nov 01, 2019	SELL	$42.77 - $50.71 $2.49 Million - $2.95 Million	-58,218 Reduced 15.03%	329,220 $16.7 Million
Q2 2019 Aug 02, 2019	SELL	$44.62 - $49.34 $4.96 Million - $5.49 Million	-111,242 Reduced 22.31%	387,438 $17.6 Million
Q1 2019 May 02, 2019	SELL	$45.12 - $53.8 $25,853 - $30,827	-573 Reduced 0.11%	498,680 $23.8 Million
Q4 2018 Jan 30, 2019	SELL	$48.76 - $63.23 $1.99 Million - $2.58 Million	-40,850 Reduced 7.56%	499,253 $26 Million
Q3 2018 Nov 02, 2018	SELL	$55.19 - $62.25 $910,635 - $1.03 Million	-16,500 Reduced 2.96%	540,103 $33.5 Million
Q2 2018 Aug 10, 2018	BUY	$50.53 - $62.98 $4.57 Million - $5.69 Million	90,424 Added 19.4%	556,603 $30.8 Million
Q1 2018 May 09, 2018	BUY	$59.92 - $68.98 $3.45 Million - $3.97 Million	57,577 Added 14.09%	466,179 $29.5 Million
Q4 2017 Feb 02, 2018	SELL	$59.94 - $65.35 $3.55 Million - $3.87 Million	-59,265 Reduced 12.67%	408,602 $25 Million
Q3 2017 Nov 01, 2017	BUY	$55.23 - $63.74 $25.8 Million - $29.8 Million	467,867	467,867 $29.8 Million

Others Institutions Holding BMY

# of Institutions

2,454

Shares Held

1.5B

Call Options Held

29.6M

Put Options Held

32.1M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $119B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track Mario Gabelli's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.

Account